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AbsTrACT 
background two recombinant enzymes (agalsidase 
alfa 0.2 mg/kg/every other week and agalsidase beta 
1.0 mg/kg/every other week) have been registered for 
the treatment of Fabry disease (FD), at equal high costs. 
an independent international initiative compared clinical 
and biochemical outcomes of the two enzymes.
Methods in this multicentre retrospective cohort study, 
clinical event rate, left ventricular mass index (lVMi), 
estimated glomerular filtration rate (egFr), antibody 
formation and globotriaosylsphingosine (lysogb3) levels 
were compared between patients with FD treated with 
agalsidase alfa and beta at their registered dose after 
correction for phenotype and sex.
results 387 patients (192 women) were included, 
248 patients received agalsidase alfa. Mean age at start 
of enzyme replacement therapy was 46 (±15) years. 
Propensity score matched analysis revealed a similar 
event rate for both enzymes (Hr 0.96, P=0.87). the 
decrease in plasma lysogb3 was more robust following 
treatment with agalsidase beta, specifically in men with 
classical FD (β: −18 nmol/l, P<0.001), persisting in the 
presence of antibodies. the risk to develop antibodies 
was higher for patients treated with agalsidase beta (Or 
2.8, P=0.04). lVMi decreased in a higher proportion 
following the first year of agalsidase beta treatment (Or 
2.27, P=0.03), while egFr slopes were similar.
Conclusions treatment with agalsidase beta at higher 
dose compared with agalsidase alfa does not result in a 
difference in clinical events, which occurred especially in 
those with more advanced disease. a greater biochemical 
response, also in the presence of antibodies, and better 
reduction in left ventricular mass was observed with 
agalsidase beta.
InTroduCTIon
Fabry disease (FD) (OMIM 301500) is an X linked 
lysosomal storage disorder characterised by the 
accumulation of globotriaosylceramide (Gb3) in 
several cell types due to deficiency of the enzyme 
alpha galactosidase A (aGAL) (enzyme commission 
number: 3.2.1.22).1 The disease is associated with 
potentially life-threatening complications such as 
renal failure, cardiac rhythm disturbances, heart 
failure and stroke. Circulating levels of plasma 
globotriaosylsphingosine (lysoGb3) can be used to 
differentiate between the severe classical phenotype 
and the more attenuated non-classical phenotype 
and as a biochemical marker to monitor treatment 
effects.2–4 Men with classical FD often have child-
hood onset of symptoms, and usually have one or 
more characteristic FD signs or symptoms such as 
cornea verticillata, neuropathic pain and clustered 
angiokeratoma,5 while non-classical FD gener-
ally has a later onset with more limited disease, 
often primarily affecting the heart. Despite the 
X linked inheritance pattern, women often have 
signs and symptoms of FD, but they are in general 
less severely affected.6 Classically affected women 
generally show a disease course that is similar to 
that of men with non-classical FD.7
Enzyme replacement therapy (ERT) with recom-
binant alpha galactosidase was the first available 
specific treatment for FD. In Europe and Canada, 
two ERTs have received marketing authorisation: 
agalsidase alfa (Replagal, Shire) and agalsidase 
beta (Fabrazyme, Sanofi Genzyme), while in the 
USA only agalsidase beta is licensed. Although 
the preparations are biochemically and structur-
ally very similar,8–10 there is a fivefold difference 
in recommended dose (agalsidase alfa 0.2 mg/kg/
every other week (EOW)11; agalsidase beta 1.0 mg/
kg/EOW.12 Studies have shown that treatment with 
both enzymes can delay some of the clinical compli-
cations of the disease.13–15 However, only two clin-
ical trials have directly compared the two agents: a 
small randomised controlled trial comparing both 
agents at a 0.2 mg/kg/EOW dose, which showed 
no clinically relevant differences,16 except for a 
dose-dependent decline of plasma lysoGb3 in a 
follow-up study17 and the Canadian Fabry Disease 
Initiative (CFDI), which showed no difference in 
event rate after a mean of 50 months of follow-up 
in 92 patients randomised to receive either agalsi-
dase alfa or beta at licensed doses.18
Indirect comparisons of non-randomised obser-
vational studies using agalsidase alfa or beta are 
hampered by differences in inclusion criteria, 
end points definition and an absence of stratifica-
tion for phenotype, which is an important predictor 
of the disease course.7 Also, development of 
neutralising antibodies directly against the enzymes 
has been associated with a smaller decrease of 
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lysoGb3,19 while their effect on the occurrence of clinical mani-
festations has not been fully elucidated.19 20
The current study aims to compare clinical and biochemical 
outcomes of agalasidase alfa versus beta as part of a large inter-
national, collaborative project including three European centres 
of excellence combined with data from the CFDI.
MeThods
Patients
Retrospective data from three European FD centres of excellence 
(Academic Medical Center (AMC), The Netherlands; Royal Free 
London NHS Foundation Trust, UK and the University Hospital 
Wuerzburg, Germany) were merged into one database. For the 
current analysis, these data were combined with the prospec-
tively collected 8 years follow-up data from patients who newly 
started ERT (cohort 1b) in the CFDI.21 Data included diagnostic 
data, clinical, biochemical and imaging outcomes, comorbidities 
and medication use.
Patients were included who had a definite FD diagnosis 
according to previously developed criteria,22 were treatment 
naïve and treated with either agalsidase alfa at a dose of 0.2 mg/
kg/EOW or agalsidase beta at a dose of 1.0 mg/kg/EOW for at 
least 9 months. Allocation of treatment was non-random, except 
for part of the patients from the CFDI. Initially, there was a 1:1 
ratio within the CFDI but during the shortage of agalsidase beta 
most patients started on agalsidase alfa. In one of the European 
treatment centres, agalsidase alfa was preferentially prescribed, 
while in the other agalsidase beta was predominantly prescribed. 
In the third European centre, allocation of treatment was based 
on the preferences of the patient in close consultation with 
the treating physician, without the presence of strict treatment 
guidelines.
Baseline was defined as start of ERT. Follow-up ended at 
switch to the other enzyme preparation or to a different dose, 
discontinuation of ERT or the last recorded clinic visit.
Medication with ACE inhibitors (ACEi)/angiotensin receptor 
blockers (ARBs), antiplatelet therapy and antihypertensive 
therapy was applied according to the best practices at that time.
Phenotype
Patients were categorised as classical or non-classical on the basis 
of enzyme activity and the presence or absence of characteristic 
FD symptoms (neuropathic pain, clustered angiokeratoma and/
or cornea verticillata.)5 A detailed description of the classifica-
tion method has been published previously and can be found in 
online supplementary appendix S1.7 The CFDI database did not 
always capture the same criteria for phenotype, thus pedigree 
analysis was added for some uncertain cases.
Clinical outcomes
We assessed the clinical event rate from start of therapy until first 
event or end of follow-up. Clinical and laboratory measurements 
were longitudinally analysed.
Clinical events
Clinical events were defined as follows:
 ► Renal events: chronic kidney disease (CKD) category G5 
(estimated glomerular filtration rate (eGFR) <15 mL/
min/1.73 m2), renal transplantation or dialysis.
 ► Cardiac events: implantation of an implantable cardiac defi-
brillator (ICD) or pacemaker (PM).
 ► Cerebral events: stroke or transient ischaemic attack diag-
nosed by a neurologist
 ► Death from any cause.
Renal function
Renal function was evaluated using the eGFR and the amount 
of protein excretion in urine. The eGFR was calculated using 
the CKD-EPI in adults and the Schwartz formula in children up 
to 18 years of age.23 24 The eGFR of patients who had received 
a renal transplant or were undergoing dialysis was set at 10 mL/
min/1.73 m2. Albuminuria and proteinuria excretion was catego-
rised according to Kidney Disease Improving Global Outcomes 
guidelines.24
Cardiac involvement
Cardiac involvement was assessed by echocardiography. Left 
ventricular mass index (LVMI) was calculated using the Devereux 
formula and was corrected for height (m2.7).25 The upper refer-
ence limit for men and women is 48 and 44 g/m2.7, respectively.25 
Analysis of cardiac MRI data was not feasible due to the small 
number of patients with baseline and follow-up MRIs.
LysoGb3 and antibodies
Plasma lysoGb3 levels, as reflection of the accumulation of sphin-
golipids, were measured at the AMC with tandem mass spec-
trometry using glycine or isotope-labelled lysoGb3 as internal 
standard.26 27 Results from both internal standards correlated 
very well.7 Antibodies were measured as previously described.28 
A titre of ≥6 was considered as antibody positive. Patients were 
considered antibody positive if all antibody measurements after 
treatment initiation were positive. Since antibody development 
in women is rare,19 antibodies were measured in men only. No 
lysoGb3 and antibody data were obtained from the CFDI.
statistical analysis
R (V.3.1.5) was used for statistical analysis. Data are presented 
as mean and SD or median and range where appropriate. A 
Cox proportional hazard model was used to assess the clinical 
event rate defined as first event (renal, cardiac or cerebral), or 
death. ERT type (ie, agalsidase alfa or beta), baseline eGFR, sex, 
phenotype and the interaction between sex and phenotype were 
included as covariates (full model specifications: online supple-
mentary appendix S2). Inclusion of baseline LVMI and a history 
of an event before initiation of ERT (stroke, dialysis, trans-
plantation and/or ICD/PM implantation) did not improve the 
model. Patients were censored when an event occurred or at end 
of follow-up. The proportional hazard assumption was visually 
tested by using Schoenfeld residuals. In addition, we applied 
propensity score matching in a 1:1 ratio (package: MatchIt) in 
order to assess if an uneven distribution of covariates could bias 
the results, by using callipers of width equal to 0.1 SD of the 
estimated propensity score. Propensity scores were based on 
sex, phenotype, baseline LVMI measured on echocardiography, 
baseline eGFR, events before ERT and age at initiation of ERT. 
Subsequently, we performed a Cox proportional hazard model 
on the matched data.
The proportion of patients with a decrease in LVMI 1 year 
after initiation of ERT was analysed by logistic regression. 
Mixed effect models (package: nlme) were used to analyse the 
eGFR, LVMI and lysoGb3 over time. Only adult patients were 
included in the analysis of the eGFR and LVMI. Both LVMI and 
lysoGb3 values showed a decrease in the first year followed by 
constant levels in the following years. In order to account for this 
non-linear relation between time and LVMI/lysoGb3, we used 
the change from baseline in LVMI and lysoGb3 in the respective 
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models. A random slope and random intercept were included 
when appropriate. Time on ERT, ERT type, age at start of ERT, 
sex, phenotype, ACEi/ARBs, baseline eGFR, baseline LVMI and/
or baseline lysoGb3 were included as covariates when appro-
priate (full model specifications: online supplementary appendix 
S2). Models were selected in a stepwise manner, and the Akaike 
Information Criterion (AIC) was used to evaluate the goodness 
of fit. Furthermore, eGFR analyses were stratified for low or 
high eGFR at baseline (eGFR <60 and ≥60 mL/min/1.73 m2, 
respectively). In the ∆LVMI analyses, results were stratified by 
the presence or absence of LVH at baseline. Differences in the 
prevalence of antibodies were assessed with the Fisher's exact 
test. The relation between antibody formation and the change 
in lysoGb3 over time was evaluated in by a linear mixed effect 
model. Mixed effect model assumptions were visually tested by 
diagnostic plots. Variance inflation factor was used to explore 
potential multicollinearity. P values <0.05 were considered 
statistically significant. Where appropriate, 95% CI are given. 
Results are reported in accordance with the ‘The Strength-
ening the Reporting of Observational Studies in Epidemiology’ 
statement.29
ethics statement
According to Dutch law, and after review of the AMC ethics 
committee, no approval of the study protocol was needed 
because of the observational nature of the study. All data were 
obtained from medical records. Patient records were anonymised 
and de-identified prior to analysis. All patients have provided 
consent for the use of their medical data and samples in accor-
dance with local ethics requirements.
resulTs
Patients
In total, 283 European and 104 Canadian patients (54% females) 
were included in the analysis (table 1). Mean age at start of ERT 
was 46 (±15) years. Treatment consisted of agalsidase alfa in 
248 and agalsidase beta in 139 patients with a median follow-up 
time of 4.9 (0.8–14.4) years. In general, patients treated with 
agalsidase beta were more likely to have classical disease, to have 
received a renal transplant or dialysis before start of therapy and 
to have higher lysoGb3 and lower eGFR at baseline (all P<0.05). 
Patient characteristics stratified for sex, phenotype and ERT 
type can be found in online supplementary table S1. Discontin-
uation of treatment (n=15) due to patient preferences or treat-
ment failure, change in dose (n=48) or switch of ERT (n=37) 
occurred in 100 patients (26%), which resulted in censoring. 
The shortage of agalsidase beta was the main reason to reduce 
dose (n=47) or switch to agalsidase alfa (n=17).
Clinical events
One or more events occurred in 103 patients (27%). In the 
agalsidase alfa group 65/248 (26%) patients developed a clinical 
event compared with 38/139 (27%) patients receiving agalsi-
dase beta. Cardiac events (n=54) were most common as first 
event after initiation of ERT, cerebral events (n=25) and renal 
events (n=10) were less frequent. Ten patients died without 
experiencing any other event during treatment. Causes of death 
in these patients were congestive heart failure (n=2), sudden 
cardiac death (n=2), secondary complications of end-stage renal 
disease (n=2), stroke (n=1), hepatic encephalopathy (n=1), 
meningitis (n=1) and ovarian cancer (n=1).
The event rate of patients treated with agalsidase alfa or 
beta was similar when stratified for sex and phenotype and 
adjusted for age at initiation of ERT and baseline eGFR (HRalfa 
vs beta: 0.96, 95% CI 0.59 to 1.57, P=0.87). A sensitivity analysis 
with addition of a decrease in eGFR of ≥33% and an increase 
in LVMI of ≥20% to the definition of clinical events revealed 
similar results (HRalfa vs beta: 0.84, 95% CI 0.55 to 1.29, P=0.44). 
Likewise, neither the inclusion of LVMI (n=314) as covariate 
to the original analysis (HRalfa vs beta: 0.94, 95% CI 0.55 to 1.59, 
P=0.81), nor the exclusion of patients with a renal event before 
treatment initiation (n=20) (HRalfa vs beta: 0.84, 95% CI 0.50 to 
1.40, P=0.50) changed the results. With propensity scores, 188 
patients were matched in a 1:1 ratio. The subsequent Cox regres-
sion analysis showed similar results (HRalfa vs beta: 0.98, 95% CI 
0.55 to 1.77, P=0.95) as the unmatched analyses (figure 1).
renal function
Longitudinal data on eGFR was available for 337 adult patients 
(figure 2). Adjusted for sex and phenotype, there was no differ-
ence in the slope of eGFR between agalsidase alfa and beta 
in patients with a baseline eGFR ≥60 (βslope alfa-beta: −0.12 mL/
Table 1 Patient characteristics at start of ERT
Agalsidase alfa 
(0.2 mg/kg)
Agalsidase beta 
(1.0 mg/kg) P value
Patients 248 139
Men, classical* 69 (28%) 71 (51%) <0.001
Men, non-classical 47 (19%) 7 (5%) 0.22
Women, classical 95 (38%) 43 (30%) 0.14
Women, non-classical 37 (15%) 18 (13%) 0.86
ERT start <18 years of age 15 (6%) 3 (2%) 0.13
Follow-up time (years) 5.2 (0.8–14.4) 3.8 (0.8–12.1) <0.001
Events before initiation of ERT
  Dialysis/renal transplant 8 (3%) 12 (9%) 0.007
  PM/ICD 21 (8%) 9 (7%) 0.87
  Stroke 22 (9%) 17 (12%) 0.09
  Any of the above† 46 (19%) 31 (22%) 0.08
LysoGb3 (nmol/L) 10 (0.7–146) 80 (2.0–178) <0.001
eGFR (mL/min/1.73 m2) 89 (10–159) 86 (10–140) 0.009
CKD category A3 44/195 (23%) 42/113 (37%) 0.008
LVMI (g/m2.7) 49 (15–117) 52 (20–148) 0.14
Use of ACEi/ARBs 89/248 (36%) 52/139 (37%) 0.83
Hypertension 109/236 (39%) 62/137 (45%) 0.23
BMI (kg/m2) 26 (±4.9) 25 (±5.6) 0.30
HDL cholesterol (mmol/L) 1.5 (±0.4) 1.5 (±0.4) 0.92
LDL cholesterol (mmol/L) 2.7 (±0.9) 2.7 (±0.8) 0.76
Total cholesterol (mmol/L) 4.8 (±1.1) 4.7 (±1.0) 0.51
Triglycerides (mmol/L) 1.2 (0.2–5.9) 1.2 (0.3–3.6) 0.18
Continuous variables are presented as mean (±SD) or median (range). Hypertension 
is defined as a diagnosis of increased blood pressure by the treating physician.
CKD category A3 is defined as AER > 300 g/day or equivalent. Missing values 
(percentage): lysoGb3 (54%), eGFR (5%), LVMI (18%), BMI (5%), HDL cholesterol 
(28%), LDL cholesterol (18%), total cholesterol (17%), triglycerides (17%). For 
baseline characteristics per sex and phenotype see online supplementary table S1, 
for detailed genotype-phenotype information see online supplementary table S2. 
*Classical, strictly defined including the presence of at least one characteristic 
symptom (angiokeratoma, acroparesthesia or cornea verticillata).
†Reflects the number of patients with one or more events (either dialysis or renal 
transplant, PM/ICD and/or stroke).
ERT, enzyme replacement therapy; PM, pacemaker; ICD, implantable cardiac 
device; lysoGb3, globotriaosylsphingosine; eGFR, estimated glomerular filtration 
rate; CKDA, chronic kidney disease albuminuria categories; LVMI, left ventricular 
mass index measured by echocardiography; ACEi, ACE inhibitors; ARB, angiotensin 
receptor blocker; BMI, body mass index; HDL, high-density lipoprotein cholesterol; 
LDL, low-density lipoprotein cholesterol.
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min/1.73 m2/year, 95% CI −0.76 to 0.51, P=0.70). Also, in 
patients with an eGFR <60 there was no difference in the rate 
of decline (βslope alfa-beta: −0.85 mL/min/1.73 m2/year, 95% CI 
−2.31 to 0.62, P=0.26). Adding the use of ACEi/ARBs and/or 
the presence of proteinuria at baseline as covariates to the model 
did not result in a better fit or different results. Our previous 
study30 showed that in this cohort (with exception of Canadian 
patients) of patients, the eGFR slope was −2.5 mL/min/1.73 m2/
year (95% CI −2.9 to −2.1, P<0.001) for classical men with a 
baseline eGFR >60 mL/min/1.73 m2 and −4.5 mL/ min/1.73 m2/
year (95% CI −5.6 to −3.3, P<0.001) for classical men with a 
baseline eGFR <60 mL/min/1.73 m2. The eGFR slope of women 
and non-classical patients with an eGFR >60 mL/min/1.73 m2 
were between −1.4 and −1.6 (all P<0.001). For women and 
non-classical patients with an eGFR <60 mL/min/1.73 m2 
only non-classical men (−3.3 mL/ min/1.73 m2/year, 95% CI 
−5.1 to −1.5, P<0.001) and non-classical women (−1.5 mL/ 
min/1.73 m2/year, 95% CI −2.8 to −0.2, P=0.04) showed a 
change in eGFR.
left ventricular mass
Two hundred and seventy-eight adult patients were included in 
the longitudinal analysis of LVMI. In patients without LVH at 
baseline (n=110), there was no change in LVMI after 1 year of 
treatment. In patients with LVH (n=168), there was a decrease 
after 1 year of treatment. The magnitude of the decrease 
depended on the LVMI at baseline (P<0.001) and was indepen-
dent of sex and phenotype (figure 3). Patients with an LVMI 
above the reference value but <75 g/m2.7, that were treated with 
agalsidase beta showed a larger but non-significant decrease of 
LVMI over the first year compared with alfa (βalfa-beta: −3.31 g/
m2.7, 95% CI −6.84 to 0.23, P=0.07), but no difference for 
the entire group was found (βalfa-beta: −2.26 g/m2.7, 95% CI 
−5.39 to 0.87, P=0.15). The decrease over the first year was 
followed by stabilisation of LVMI in the following years (βtime 
on ERT: 0.22, P=0.33). Hence, the observed difference between 
agalsidase alfa and beta over the first year persisted during the 
following years.
Figure 1 Kaplan-Meier curve after propensity score matching. Kaplan-Meier curve for any first event (renal, cardiac or cerebral event or death) after 
propensity score matching. 
Figure 2 estimated glomerular filtration rate (egFr) vs time on enzyme replacement therapy (ert). linear mixed model of egFr adjusted for sex and 
phenotype, stratified for baseline egFr <60 and ≥60 ml/min/1.73 m2. the larger lines represent the predicted values at group level, the smaller lines 
represent the predicted values at individual patient level.
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The analysis on the number of patients that showed a decrease 
in LVMI after 1 year of treatment revealed that treatment with 
agalsidase beta resulted in a higher proportion of patients with a 
decrease in LVMI compared with agalsidase alfa (79% vs 62%) 
(OR 2.27, 95% CI 1.11 to 4.86, P=0.03), adjusted for the LVMI 
at baseline.
lysoGb3
Longitudinal data on lysoGb3 was available for 153 patients 
(figure 4). After initiation of ERT, lysoGb3 concentrations 
rapidly decreased, followed by stabilisation in all subgroups 
(men with classical FD: β: 0.83 nmol/L/year, P=0.08; men with 
non-classical FD and women: β: 0.03 nmol/L/year, P=0.94). 
After adjustment for baseline lysoGb3 concentration, sex and 
phenotype, the decrease in lysoGb3 (∆lysoGb3) in men with 
classical FD was more pronounced in those treated with agalsi-
dase beta (βalfa-beta: −18.06 nmol/L, 95% CI −25.81 to −10.03, 
P<0.001). For example, in a classically affected man with a 
baseline lysoGb3 value of 100 nmol/L, the lysoGb3 concentra-
tion will be on average 45 nmol/L following 1 year of treatment 
with agalsidase alfa and 27 nmol/L after 1 year of treatment with 
agalsidase beta. In the other patients (women and non-classical 
men), this difference was also significant but smaller (βalfa-beta: 
−1.07 nmol/L, 95% CI −2.04 to −0.11, P=0.03).
Antibodies
One or more antibody assays were performed for 124 men. 
From 32 non-classical men (agalsidase alfa: n=27, agalsidase 
beta: n=5), only one developed transient antibodies. Antibody 
measurements were available for 92 classical men. Patients with 
a mixed antibody response over time (negative as well as posi-
tive antibody measurements) were excluded (n=11). Of the 
remaining 81 patients, persisting antibodies were established in 
33 men, of whom 11 were treated with agalsidase alfa (11/39, 
28%) and 22 with agalsidase beta (22/42, 52%) resulting in an OR 
of 2.8 (95% CI 1.02 to 7.88, P=0.041). Results did not change 
substantially if the first antibody measurements of patients with 
a mixed antibody response were included (OR 3.14, P=0.011). 
Antibody titres remained stable over time (figure 5).
A comparison of the clinical event rate, LVMI and eGFR 
between patients treated with agalsidase alfa and agalsidase beta 
with or without antibodies was hampered by the uneven distri-
bution of disease severity among groups. The limited number of 
patients (n=81) and events in these groups (n=29) makes exten-
sive correction for disease severity variables impossible.
Analysis of the influence of antibodies on the decrease in 
lysoGb3 in men with classical FD treated with agalsidase alfa 
(n=21) or beta (n=35) revealed the following: in patients 
treated with agalsidase alfa the presence of antibodies was asso-
ciated with a less prominent decrease in lysoGb3 following ERT, 
resulting in 34.77 nmol/L (95% CI 23.65 to 45.88, P<0.001, 
adjusted for baseline lysoGb3 concentrations) higher lysoGb3 
concentrations in the antibody-positive group compared with 
the antibody-negative group. In patients receiving agalsidase 
beta, the decrease in lysoGb3 after ERT initiation was minimally 
affected by the presence or absence of antibodies (β
AB+ vs AB−: 
6.72 nmol/L, 95% CI −1.43 to 14.87, P=0.10) (figure 6).
dIsCussIon
In this study, we systematically compared clinical outcomes and 
biochemical response in a large cohort of almost 400 patients 
with Fabry disease treated with either agalsidase alfa or agalsi-
dase beta at authorised dose. There is no difference in clinical 
event rate between both enzymes, but treatment with agalsi-
dase beta results in a larger decrease in lysoGb3 concentrations 
compared with agalsidase alfa. In addition, treatment with 
agalsidase beta has a better effect on left ventricular mass, in 
patients with a LVMI <75 g/m2.7. Fewer patients had an immu-
nological response to agalsidase alfa as compared with agalsi-
dase beta. There were considerable baseline differences between 
Figure 4 lysogb3 vs time on enzyme replacement therapy (ert) in men 
with classical Fabry disease. linear mixed model of lysogb3 adjusted for 
lysogb3 at baseline. the figure presents data of men with the classical 
phenotype. the larger lines represent the predicted values at group level, 
the smaller lines represent the raw individual patient data.
Figure 3 change in left ventricular mass index (lVMi) in relation to 
the lVMi at baseline. estimates of the change in lVMi from baseline after 
1 year per patient, results from the linear mixed model of the change in 
lVMi.
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both treatment groups, which could be explained by differences 
in proportions of patients with classical FD as well as prescrip-
tion behaviour between centres. In order to account for these 
differences, all analyses were adjusted for phenotype and disease 
severity.
In line with our findings, a small observational study 
showed that treatment with agalsidase beta resulted in a more 
pronounced decrease in lysoGb3 compared with agalsidase 
alfa.17 Furthermore, a slight increase in lysoGb3 was observed 
in men with classical FD who received a lower dose or switched 
to agalsidase alfa during the shortage of agalsidase beta.31 Also, 
a correlation between cumulative dose and podocyte Gb3 
clearance has been reported.32 A dose effect on biochemical 
markers is further supported by the observations from this study 
on the influence of neutralising antibodies. We confirmed the 
higher prevalence of neutralising antibodies in patients treated 
with agalsidase beta.11 12 19 This may be related to the dose or the 
manufacturing method of the product (ie, human vs CHO cell 
line and the possible differences in glycosylation).8–10 The vast 
majority of neutralising antibodies in FD are IgG antibodies.28 33 
IgE-mediated reactions are very infrequently observed, and have 
only been reported for patients treated with agalsidase beta.33 
Severe anaphylaxis is rare and infusion-related reactions are 
usually well manageable with antipyretic drugs and/or low-dose 
corticosteroids prior to the infusion. The presence of antibodies 
in patients treated with agalsidase alfa is associated with a less 
prominent decrease in lysoGb3, while the decrease in lysoGb3 is 
almost unaffected by antibody formation during treatment with 
agalsidase beta, which has also been found in an earlier study.17 
This is most likely caused by the fivefold higher dose, which 
overcomes the negative effects of antibody formation. In other 
lysosomal storage disorders, such as Gaucher disease, biochem-
ical markers including glucosylsphingosine, correlate well with 
clinical disease parameters and can be used to monitor the effect 
of therapeutic intervention.4 34 In FD, previous studies have 
shown that plasma lysoGb3 is derived from the storage material 
and is related to phenotype and disease severity.3 7 35 In addi-
tion, lysoGb3 levels are associated with Mainz Severity Score 
index (MSSI) scores and LVMI in men and the presence of white 
matter lesions (WML) in women.36 Although most previous 
studies were unable to show differences in clinical outcomes 
between antibody-negative and antibody-positive patients,19 37 38 
a more recent study showed larger LVMI and worse renal func-
tion in patients with antibodies.20 In that study, however, no 
differentiation was made by phenotype, and results were only 
adjusted for having a nonsense mutation. This has probably led 
to a confounding effect of phenotype, since the most severely 
affected patients (ie, classical patients) are most likely to develop 
antibodies. Correction for phenotype in the current study limits 
the risk of this bias and made it impossible to analyse differences 
in clinical outcome between those with and without antibodies.
No direct relationship between the decrease in lysoGb3 can be 
established with the clinical outcome. A reason for this is that the 
lysoGb3 merely reflects reduction in storage material. In some 
Figure 5 antibody titres in men with classical Fabry disease. antibody titres per patient. the solid dark line represent the cut-off, at an antibody titre of 6. 
Figure 6 effect of antibody formation on lysogb3 in men with classical 
Fabry disease. linear mixed model of the change in lysogb3 adjusted for 
lysogb3 at baseline, stratified for enzyme replacement therapy (ert) type 
and antibody status. the larger lines represent the predicted values at 
group level (at the mean lysogb3 concentration of 105 nmol/l in these 
patients), the smaller lines represent the predicted values at individual 
patient level.
group.bmj.com on March 6, 2018 - Published by http://jmg.bmj.com/Downloaded from 
7Arends M, et al. J Med Genet 2018;0:1–8. doi:10.1136/jmedgenet-2017-104863
Therapeutics
patients, the observed dose effect on plasma lysoGb3 may not 
always be followed by clinically relevant outcomes. Recently, we 
have described the absolute slopes for eGFR, LVMI of patients 
on treatment stratified for phenotype and sex which might be 
used as benchmark for future studies.30 This study also empha-
sises the fact that in some patients there is irreversible damage 
to organs such as the kidneys, which will not be reversed. It was 
shown that in patients with advanced kidney disease, the risk 
(HR 2.7) to develop new complications is high, despite treat-
ment.38 Left ventricular hypertrophy has been shown to be 
reversible to some extent although the presence of fibrosis in the 
heart hampers an effect of any therapy.14 30 39 Hence, the direct 
relationship between biochemical and clinical response cannot 
be expected. We believe however, that an optimal biochemical 
response is a prerequisite for a clinical response. Indeed, this 
study shows that a better effect of agalsidase beta was established 
during the first year of treatment. However, no effect on eGFR 
or clinical event rate could be established. Indeed, the presence 
of irreversible organ damage might be the reason why disease 
progression has been observed in patients receiving ERT, leading 
to only a modest clinical effect of ERT. Although a clear effect of 
dose is observed on biochemical outcomes, the fact that several 
patients were in an advanced and irreversible disease state limits 
the potential to observe a similar magnitude of effect on clin-
ical outcomes. It is also possible that the current study is still 
underpowered to detect a significant difference in event rate. 
The CFDI investigators previously calculated that almost 300 
patients per group (ie, 600 patients in total) would be required 
to detect a 10% difference,18 which is more than the nearly 400 
patients we were able to include, even after combining data 
from three European referral centres and the CFDI. Likewise, 
none of the studies that evaluated the effects of switching or 
dose reduction during the shortage of agalsidase beta was able to 
show a change in clinical event rate, since the cohorts were often 
small and had relatively short follow-up.31 40–42 Nonetheless, the 
results of one of the largest studies suggested a steeper decline 
in eGFR and higher disease severity scores in patients who had 
been switched or received a lower dose.42
Besides the possibility that the present study is underpowered 
to detect a difference in event rate, there are some other limita-
tions. First of all, allocation of treatment was not random, except 
for part of the patients from the CFDI, although randomisation 
in this cohort was hampered by the shortage of agalsidase beta. 
Second, data were not collected through a uniform protocol and 
although data were mostly prospectively collected at the indi-
vidual centres, the information was merged at a later time point. 
Finally, lysoGb3, antibody measurements and MRI scans were 
only available for a subset of patients. In conclusion, although we 
were unable to show a difference in event rate between patients 
treated with agalsidase alfa and beta, our results suggest a more 
pronounced reduction of storage materials, with agalsidase beta.
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